Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
How Tirzepatide May Help Near-surgical weight loss: 22.5% average weight loss rivals bariatric outcomes that produce 56% to 80% GERD resolution Visceral fat targeting: Preferential reduction of the fat depot most directly linked to reflux severity Lower vomiting risk: 5% to 9% rate is safer for patients with esophagitis compared to semaglutide's 24% Metabolic syndrome correction: Addresses multiple GERD risk factors simultaneously Inflammation reduction: 35% to 42% CRP reduction supports overall esophageal healing Important Safety Information Tirzepatide carries a boxed warning for thyroid C-cell tumors in rodent studies
Participants showed improvements in CRP levels and other acute-phase reactants, suggesting inflammation reduction occurs through both weight-dependent and weight-independent pathways
CagriSema is a fixed-dose combination of cagrilintide plus semaglutide
PubMed: 18644225 BPC-157 blood-vessel signaling nitric-oxide signaling, VEGF-related pathways, and growth-hormone receptor expression in cell and animal models: Hsieh MJ et al
PlexusDx maps 14 distinct metabolic pathways and 150+ genetic insights to support personalized treatment planning
